These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles]. Miyata K; Honda K Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):143-52. PubMed ID: 7959407 [TBL] [Abstract][Full Text] [Related]
8. Recent advances with 5-HT Juza R; Vlcek P; Mezeiova E; Musilek K; Soukup O; Korabecny J Med Res Rev; 2020 Sep; 40(5):1593-1678. PubMed ID: 32115745 [TBL] [Abstract][Full Text] [Related]
9. Spectrum of use and tolerability of 5-HT3 receptor antagonists. Haus U; Späth M; Färber L Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406 [TBL] [Abstract][Full Text] [Related]
10. Serotonin and psychiatric disorders. A key to new therapeutic approaches. Costall B; Naylor RJ Arzneimittelforschung; 1992 Feb; 42(2A):246-9. PubMed ID: 1586395 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties and functions of central 5-HT3 receptors. Costall B; Naylor RJ Therapie; 1991; 46(6):437-44. PubMed ID: 1840228 [TBL] [Abstract][Full Text] [Related]
13. The breadth of action of the 5-HT3 receptor antagonists. Costall B Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():3-9. PubMed ID: 8201244 [TBL] [Abstract][Full Text] [Related]
14. Opportunities for treatment of psychoactive substance use disorders with serotonergic medications. Sellers EM; Higgins GA; Tomkins DM; Romach MK; Toneatto T J Clin Psychiatry; 1991 Dec; 52 Suppl():49-54. PubMed ID: 1752860 [TBL] [Abstract][Full Text] [Related]
15. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Cunningham RS Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379 [TBL] [Abstract][Full Text] [Related]
16. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models. Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753 [TBL] [Abstract][Full Text] [Related]
17. Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice. Rodgers RJ; Cole JC; Tredwell JM Psychopharmacology (Berl); 1995 Feb; 117(3):306-12. PubMed ID: 7770606 [TBL] [Abstract][Full Text] [Related]
18. Antipsychotic medications for children and adolescents. Gracious BL; Findling RL Pediatr Ann; 2001 Mar; 30(3):138-45. PubMed ID: 11257943 [No Abstract] [Full Text] [Related]
19. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Humphrey PP; Bountra C; Clayton N; Kozlowski K Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738 [TBL] [Abstract][Full Text] [Related]
20. The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models. Artaiz I; Romero G; Zazpe A; Monge A; Calderó JM; Roca J; Lasheras B; Del Río J Psychopharmacology (Berl); 1995 Jan; 117(2):137-48. PubMed ID: 7753959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]